Marc de Garidel has served as Abivax's Chief Executive Officer since May 5, 2023 and served as Interim Chairman of the Board from May 2023 to July 2024. He has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years as a biotech and pharmaceutical CEO. Between July 2021 and April 2023 he was Chief Executive Officer of CinCor Pharma, leading its sale for up to $1.8 billion to AstraZeneca in February 2023; from September 2020 to May 2021 he was CEO of AZTherapies; and from April 2018 to August 2020 he was CEO of Corvidia Therapeutics, which he led to a $2.1 billion sale to Novo Nordisk. He was Chief Executive Officer of Ipsen from November 2010 to July 2016 and earlier held roles of increasing responsibility at Amgen and Eli Lilly. He has chaired the board of Ipsen since 2010 and has been a director of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master's degree in International Management from Thunderbird School of Global Management, and an executive MBA from Harvard Business School.